日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

A plain language summary of two trials for larotrectinib in people with TRK fusion-positive lung cancer to learn how well the drug works and how safe it is

本文以通俗易懂的语言总结了两项针对TRK融合阳性肺癌患者的拉罗替尼试验,旨在了解该药物的疗效和安全性。

Drilon, Alexander; Lin, Jessica J; Burcoveanu, Domnita-Ileana; Ollis, Christopher; Reiss, Matthew; Torberger, Oskar; Moreno, Victor